Outcomes and treatment patterns in primary and secondary plasma cell leukemia: insights from a large US cohort study
Plasma cell leukemia (PCL) is a rare and aggressive plasma cell disorder with a short survival duration despite the use of novel therapeutics. PCL remains an understudied disease for which there is no current standard of care treatment. Knowledge on optimal novel drug sequencing, including the role...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Ferrata Storti Foundation
2025-04-01
|
| Series: | Haematologica |
| Online Access: | https://haematologica.org/article/view/12031 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850197690147667968 |
|---|---|
| author | Shagun Singh Supriya Peshin Betsy C. Wertheim Ashley Larsen Iloabueke Chineke Douglas W. Sborov Damian Green Michaela Liedtke Marie Okoniewski Mohammed Wazir Omar Nadeem Levanto G. Schachter Dominique DeGraaff Victoria A. Vardell David G. Coffey Krisstina Gowin |
| author_facet | Shagun Singh Supriya Peshin Betsy C. Wertheim Ashley Larsen Iloabueke Chineke Douglas W. Sborov Damian Green Michaela Liedtke Marie Okoniewski Mohammed Wazir Omar Nadeem Levanto G. Schachter Dominique DeGraaff Victoria A. Vardell David G. Coffey Krisstina Gowin |
| author_sort | Shagun Singh |
| collection | DOAJ |
| description |
Plasma cell leukemia (PCL) is a rare and aggressive plasma cell disorder with a short survival duration despite the use of novel therapeutics. PCL remains an understudied disease for which there is no current standard of care treatment. Knowledge on optimal novel drug sequencing, including the role and timing of hematopoietic stem cell transplant as primary and salvage therapy is needed. We conducted a large retrospective analysis of 153 PCL patients, using the new definition of ≥ 5% circulating plasma cells, including clinical features and treatment outcomes across seven academic centers in United States. This is, to the best of our knowledge, the largest multicenter study conducted in the US of this rare disease. Disease presentation, clinical and genetic characteristics, and treatment patterns of 93 patients with primary PCL and 57 with secondary PCL were described. Additionally, associations between patient characteristics and mortality were investigated using Cox proportional-hazards regression models. Secondary PCL was associated with a worse prognosis, with a median overall survival of 3.2 months compared to 36.6 months for primary PCL (p |
| format | Article |
| id | doaj-art-d6123ae67daa47f784e0ff1486a25da1 |
| institution | OA Journals |
| issn | 0390-6078 1592-8721 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Ferrata Storti Foundation |
| record_format | Article |
| series | Haematologica |
| spelling | doaj-art-d6123ae67daa47f784e0ff1486a25da12025-08-20T02:13:03ZengFerrata Storti FoundationHaematologica0390-60781592-87212025-04-01999110.3324/haematol.2024.287158Outcomes and treatment patterns in primary and secondary plasma cell leukemia: insights from a large US cohort studyShagun Singh0Supriya Peshin1Betsy C. Wertheim2Ashley Larsen3Iloabueke Chineke4Douglas W. Sborov5Damian Green6Michaela Liedtke7Marie Okoniewski8Mohammed Wazir9Omar Nadeem10Levanto G. Schachter11Dominique DeGraaff12Victoria A. Vardell13David G. Coffey14Krisstina Gowin15Internal Medicine, Banner University Medical CenterNorton Community Hospital, Ballad HealthUniversity of Arizona Cancer CenterDepartment of Medicine, University of ArizonaRocky Mountain Oncology, Casper, WYHuntsman Cancer Institute at the University of Utah, Salt Lake City, UTUniversity of Miami, Miller School of Medicine, Miami, FLStandford Medicine, Department of Hematology, Palo Alto, CAUniversity of Kansas Cancer Center, Kansas City, KSUMass Memorial Medical Center, Division of Hematology/Oncology, Worcester, MAHarvard Medical School, Dana-Faber Cancer InstituteUCLA Health, Hematology Oncology, San Luis Obispo, CAUniversity of Washington, Department of Oncology and Hematology, Seattle, WAUniversity of Utah, Huntsman Cancer Institute, Salt Lake City, UTDivison of Myeloma, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FLDepartment of Supportive Care Medicine, Hematology/HCT, City of Hope, CA Plasma cell leukemia (PCL) is a rare and aggressive plasma cell disorder with a short survival duration despite the use of novel therapeutics. PCL remains an understudied disease for which there is no current standard of care treatment. Knowledge on optimal novel drug sequencing, including the role and timing of hematopoietic stem cell transplant as primary and salvage therapy is needed. We conducted a large retrospective analysis of 153 PCL patients, using the new definition of ≥ 5% circulating plasma cells, including clinical features and treatment outcomes across seven academic centers in United States. This is, to the best of our knowledge, the largest multicenter study conducted in the US of this rare disease. Disease presentation, clinical and genetic characteristics, and treatment patterns of 93 patients with primary PCL and 57 with secondary PCL were described. Additionally, associations between patient characteristics and mortality were investigated using Cox proportional-hazards regression models. Secondary PCL was associated with a worse prognosis, with a median overall survival of 3.2 months compared to 36.6 months for primary PCL (phttps://haematologica.org/article/view/12031 |
| spellingShingle | Shagun Singh Supriya Peshin Betsy C. Wertheim Ashley Larsen Iloabueke Chineke Douglas W. Sborov Damian Green Michaela Liedtke Marie Okoniewski Mohammed Wazir Omar Nadeem Levanto G. Schachter Dominique DeGraaff Victoria A. Vardell David G. Coffey Krisstina Gowin Outcomes and treatment patterns in primary and secondary plasma cell leukemia: insights from a large US cohort study Haematologica |
| title | Outcomes and treatment patterns in primary and secondary plasma cell leukemia: insights from a large US cohort study |
| title_full | Outcomes and treatment patterns in primary and secondary plasma cell leukemia: insights from a large US cohort study |
| title_fullStr | Outcomes and treatment patterns in primary and secondary plasma cell leukemia: insights from a large US cohort study |
| title_full_unstemmed | Outcomes and treatment patterns in primary and secondary plasma cell leukemia: insights from a large US cohort study |
| title_short | Outcomes and treatment patterns in primary and secondary plasma cell leukemia: insights from a large US cohort study |
| title_sort | outcomes and treatment patterns in primary and secondary plasma cell leukemia insights from a large us cohort study |
| url | https://haematologica.org/article/view/12031 |
| work_keys_str_mv | AT shagunsingh outcomesandtreatmentpatternsinprimaryandsecondaryplasmacellleukemiainsightsfromalargeuscohortstudy AT supriyapeshin outcomesandtreatmentpatternsinprimaryandsecondaryplasmacellleukemiainsightsfromalargeuscohortstudy AT betsycwertheim outcomesandtreatmentpatternsinprimaryandsecondaryplasmacellleukemiainsightsfromalargeuscohortstudy AT ashleylarsen outcomesandtreatmentpatternsinprimaryandsecondaryplasmacellleukemiainsightsfromalargeuscohortstudy AT iloabuekechineke outcomesandtreatmentpatternsinprimaryandsecondaryplasmacellleukemiainsightsfromalargeuscohortstudy AT douglaswsborov outcomesandtreatmentpatternsinprimaryandsecondaryplasmacellleukemiainsightsfromalargeuscohortstudy AT damiangreen outcomesandtreatmentpatternsinprimaryandsecondaryplasmacellleukemiainsightsfromalargeuscohortstudy AT michaelaliedtke outcomesandtreatmentpatternsinprimaryandsecondaryplasmacellleukemiainsightsfromalargeuscohortstudy AT marieokoniewski outcomesandtreatmentpatternsinprimaryandsecondaryplasmacellleukemiainsightsfromalargeuscohortstudy AT mohammedwazir outcomesandtreatmentpatternsinprimaryandsecondaryplasmacellleukemiainsightsfromalargeuscohortstudy AT omarnadeem outcomesandtreatmentpatternsinprimaryandsecondaryplasmacellleukemiainsightsfromalargeuscohortstudy AT levantogschachter outcomesandtreatmentpatternsinprimaryandsecondaryplasmacellleukemiainsightsfromalargeuscohortstudy AT dominiquedegraaff outcomesandtreatmentpatternsinprimaryandsecondaryplasmacellleukemiainsightsfromalargeuscohortstudy AT victoriaavardell outcomesandtreatmentpatternsinprimaryandsecondaryplasmacellleukemiainsightsfromalargeuscohortstudy AT davidgcoffey outcomesandtreatmentpatternsinprimaryandsecondaryplasmacellleukemiainsightsfromalargeuscohortstudy AT krisstinagowin outcomesandtreatmentpatternsinprimaryandsecondaryplasmacellleukemiainsightsfromalargeuscohortstudy |